|Title:||Predictors of quality of life and other patient-reported outcomes in the PANORAMA multinational study of people with type 2 diabetes||Authors:||Bradley, Clare
De Pablos-Velasco, Pedro
Parhofer, Klaus G.
|UNESCO Clasification:||32 Ciencias médicas||Keywords:||Treatment Satisfaction
Trial, et al
|Issue Date:||2018||Journal:||Diabetes Care||Abstract:||OBJECTIVE PANORAMA, a nine-country cross-sectional type 2 diabetes study, investigated factors associated with quality of life (QoL), health status, and other patient-reported outcome measures (PROMs). RESEARCH DESIGN AND METHODS Patients were randomly or consecutively selected from primary/secondary care. PROMs included the Audit of Diabetes-Dependent Quality of Life (ADDQoL) (generic QoL item and average weighted impact [AWI] scores), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (patient- and physician-completed), Hypoglycemia Fear Survey-II worry subscale, and the EuroQoL–5 Dimension visual analog scale (EQ-VAS) measuring patient-reported health. Multivariable linear regression analyses determined predictors of each PROM including patient characteristics, physician-reported adherence, complications, and glycosylated hemoglobin. RESULTS In 5,813 patients, mean PROM scores indicated that generic QoL approximated “good” (0.93); perceived impact of diabetes on QoL was negative (AWI –1.69). Treatment satisfaction exceeded physicians’ estimates (patient-reported: 29.76; physician-estimated: 27.75), but so did patients’ perceived frequency of hypo-/hyperglycemia. Worry about hypoglycemia (13.27) was apparent. Intensifying treatments to three oral agents or insulin regimens predicted worse QoL (AWI P < 0.01). Insulin alone use predicted worse QoL (generic P < 0.02; AWI P < 0.001) and hypoglycemia worry (P < 0.007). No treatment had significant associations with EQ-VAS health status. CONCLUSIONS Predictors for different PROMs differed markedly and provided insights for understanding and improving these important outcomes. Intensive treatment regimens had significant negative associations with all PROMs, except the EQ-VAS health status measure. The findings demonstrate the importance of measuring QoL alongside health status and other patient-reported outcomes when evaluating diabetes treatments with a view to protecting QoL and facilitating adherence and long-term glycemic control.||URI:||http://hdl.handle.net/10553/41834||ISSN:||0149-5992||DOI:||10.2337/dc16-2655||Source:||Diabetes Care [ISSN 0149-5992], v. 41 (2), p. 267-276|
|Appears in Collections:||Artículos|
checked on Jan 29, 2023
WEB OF SCIENCETM
checked on Jan 29, 2023
checked on Aug 27, 2022
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.